ArticleAmerican journal of translational research2025
Analysis of dapagliflozin combination therapy in heart failure with reduced ejection fraction and its correlation with inflammatory markers.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metabolic inflexibility across heart failure phenotypes: mechanisms and type-specific therapeutic implications.Apoptosis : an international journal on programmed cell death · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the effects of the sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin on myocardial function, inflammatory markers, and cardiovascular outcomes in patients with heart failure with reduced ejection fraction (HFrEF).
methodsA retrospective analysis was conducted on 107 hospitalized patients with HFrEF treated at our hospital between November 2022 and October 2024. Based on the treatment regimen, patients were divided into a control group (n = 52), which received standard therapy [diuretics, β-blockers, angiotensin-converting enzyme inhibitors (ACEIs), and aldosterone antagonists], or into a dapagliflozin group (n = 55), which received dapagliflozin in addition to standard therapy. Outcomes assessed included: clinical efficacy; cardiac function [left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), and left ventricular ejection fraction (LVEF)]; myocardial work indices [global work index (GWI), global constructive work (GCW), global wasted work (GWW), and global work efficiency (GWE)]; energy metabolism [free fatty acids (FFA) and β-hydroxybutyric acid (β-HB)], inflammatory markers [interleukin-1β (IL-1β), IL-6, tumor necrosis factor-α (TNF-α), and IL-10]; quality of life, and the incidence of cardiovascular and other adverse reactions.
resultsThe dapagliflozin group achieved a significantly higher overall clinical efficacy rate than the control group (94.55% vs. 80.77%; P < 0.05). After 8 weeks of treatment, patients receiving dapagliflozin in addition to standard therapy showed significantly greater improvements in multiple cardiac function parameters compared to those receiving standard therapy alone (P < 0.05). GWI, GCW, and GWE were significantly higher, and GWW significantly lower, in the dapagliflozin group (P < 0.05). Indicators of energy metabolism were significantly higher in the dapagliflozin group (P < 0.05). Pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) decreased, whereas the anti-inflammatory cytokine IL-10 increased more markedly in the dapagliflozin group compared to the control group (P < 0.05). After treatment, the dapagliflozin group showed greater improvements across multiple quality-of-life dimensions, and significantly lower incidence of cardiovascular adverse events (14.55% vs. 34.62%) (P < 0.05). The overall incidence of other adverse reactions did not differ significantly between groups (P > 0.05).
conclusionIn patients with HFrEF, the addition of dapagliflozin to standard therapy provides synergistic benefits in improving cardiac function, energy metabolism, and inflammatory status. These effects translate into improved quality of life and cardiovascular outcomes, highlighting dapagliflozin's clinical value in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.